Avacta news


 

Avacta extends Optim® 2 product family for even greater measurement flexibility. Nov 20, 2018 Avacta Group Historic Prices Biotherapeutics and reagents developer Avacta Group said chief scientific More Avacta Group Market News >. April 25 (Reuters) - Avacta Group PLC: * Panmure cuts Avacta price target to 1. Find out the latest news headlines for AVACTA GROUP PLC ORD 10P (AVCT. Avacta on track to deliver pre-clinical milestones this year Avacta Group looks to Asia for partner as it plans first Affimer clinical trial. Dr Eliot Forster brings more than 25 years of experience in the pharmaceutical and biotechnology industry. Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent toxin payloads, to evaluate the use of the Avacta’s Affimer® technology in combination with Avacta Group (AVCT) fundamentals. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views. Affimer molecules have been developed for applications in Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. 3m and comprised of £0. Avacta Group, the developer of Affimer biotherapeutics and reagents, has established a commercial team of three people in the U. 225 likes · 1 was here. The company's pre-close trading update adds that on 5 August, the group was successful in raising £4. The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed sharesAvacta Group PLC stock price, stock quotes and financial overviews from MarketWatch. Affimers represent a radical alternative to the established antibody technology, which continues to Email format and list of 15 email addresses of people working at Avacta. We are now available on Facebook! NEW YORK (GenomeWeb) — British biotech firm Avacta announced on Wednesday that it has licensed its affimer technology to New England Biolabs (NEB) for use in an assay NEB is currently developing for research and diagnostic applications. Sectors and Industries Content Track sectors and industries performance, see top performing companies, and find news relevant to you. Avacta Life Sciences, Wetherby. Central Nervous System Biomarkers Market is Expected to Grow at Constant CAGR of 15. 0m. 4million to fund its work. Invest with The Share CentreAbout Avacta Group plc (www. 2m) in a round backed by commercialisation firm IP Group. 06605196. Affimer technology has been engineered as an antibody alternative. Biotechnology business Avacta Group, which has sites in Wetherby and Cambridge, has hailed the "significant operational progress" made during its latest financial year. Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Avacta Unit B, 1 Lion Works, Station Road East Whittlesford, Cambridge CB22 4WL. Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday. Hardman & Co call the lithium market: is a change in trend happening? 23 rd November 2018. View the latest Avacta (AVCT) share price and news, including recent trades, historical charts, broker views and our views. This is a UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. Registered company no. The new bioprocess analysis service - the result of the collaboration - aims to offer "a market leading analytical service to biopharmaceutical developers", Avacta said today (13 June). Follow Avacta Animal Health to stay up-to-date with news, articles and jobs. Title: Chief Executive OfficerAre Avacta Group Plc’s (LON:AVCT) Interest Costs Too High?https://finance. It has a market capitalisation of £27. Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumesAvacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday. And it reported “excellent progress” with a second immuno-oncology 2 days ago · Biotech firm Avacta Group PLC (LON:AVCT) is gaining commercial traction with its Affirmer technology after it inked a licensing deal for the tech …Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. This compact and robust system combines the powerful protein characterisation capabilities of the original Optim 1000 instrument with a new, application-oriented software package designed to increase throughput and functionali The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces its unaudited interim results for the period ended 31 January 2018. 76m for the year ending 31 July 2018, up slightly from £2. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Reuters provides trusted Learn about working at Avacta. They also assigned headlines about the biotechnology company a news buzz of 10. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Protein Engineering Society of Europe meeting, which is taking place in Lisbon on 14 November 2018. 119 Click to enlarge Notes: The following slide deck was published by Avacta Group Plc in conjunction LONDON (Alliance News) - Biotechnology firm Avacta Group PLC said Monday it appointed ex-Immunocore Ltd boss Eliot Forster as its non-executive chairman. Avacta's revenues for the year to the end of July were on target at £2. com's FREE daily email newsletter. AVACTA Share Chat and Share Discussion Board featuring the latest investing views, opinion and debate from our Forum users and external contributors on LON:AVCT. L stock chart on Yahoo Finance. Generally speaking, as a company grows, institutions will increase their ownership. Latest stock price today and the US's most active stock market forums. NEB, a global leader in the discovery and production of enzymes for molecular biology applications, is The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares Life sciences firm Avacta has reported a slight increase in revenue after successfully completing an £11. Cotrel joins Avacta from Abcam, where he held the role of commercial operations director, and will lead the group's commercial strategy and business development activities and drive the commercialisationAvacta Group (AVCT) fundamentals. We have developed a revolutionary new alternative to antibodies and YORKTEST Veterinary Services has announced a change of name to Avacta Animal Health Ltd. The results meaningfully de-risk the development of the technology as a therapeutic platform What is an allergy? An allergy is an adverse reaction to a normally harmless substance such as food or pollen (allergens). One test is defined as an Avacta Animal Health allergy test, screen with or without an expansion, or package, listed on the September 2018 price list for one individual dog, cat or horse. Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. The last earnings update was 42 days ago. View the basic AVCT. LifeArc is a charity registered with the Charity Commission for England and Wales no. 83 m, with 115,462,211 shares in issue. Title: Chief Executive OfficerAvacta in talks with pharma giants - Yorkshire Posthttps://www. Avacta Group has appointed Dr Eliot Forster as non-executive chairman to the Board. The study was designed to demonstrate that Avacta’s Affimer technology could be combined with Glythera’s Permalink conjugation chemistry to provide a technically superior drug conjugate platform with shorter development times, simpler, more consistent production and greater chemical stability. And it reported “excellent progress” with a second immuno-oncology Read all the latest Avacta Group plc (AVCT) Ordinary Shares 10p share news, regulatory announcements and tips. This information is provided by RNS, the news service of the London Stock Exchange. Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, said it is in discussions with a number of big pharmaceutical firms which could transform the group's fortunes. High quality, robust, specific, with a rapid custom service and …Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. 90P; rating buy For a summary of rating Nov 1 (Reuters) - Avacta Group PLC: * Panmure Gordon starts Avacta MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. - News - PharmaTimes About Avacta Group plc (www. Take a virtual tour of our Cambridge site. Reuters provides trusted Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. com) Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Specialist corporate lawyers at Walker Morris have advised Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, on its proposed placing and subscription at a price of 25 pence per share to raise gross proceeds for the Company of £11. Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday. Avacta has developed Affimer technology - a revolutionary new engineered affinity protein that is an alternative to antibodies. gtGTU vector was developed for gene therapy applications to ensure stable and prolonged expression of DNA-based therapeutics. 6m fundraising round. 74m in 2017. Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, said it is in discussions with a number of big pharmaceutical firms which could transform the group's fortunes. +44 (0)1223 75 Avacta to present pre-clinical development data at Lisbon conference. 4mln. High quality, robust, with a 7Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Title: Chief Executive OfficerEvolution Executive Search | Avactahttps://evolutionexec. Avacta has two business units - one focused on drug development using its novel platform development, and specialising in immunocology/cancer therapy a hot area right now. Pharmafile. Executive search firm Toft Group has placed Dr. The lowly valuation may worry some investors, but this firm, based near Wetherby, West Yorkshire, has real potential. 20 Nov 2018 Avacta Group Historic Prices Biotherapeutics and reagents developer Avacta Group said chief scientific More Avacta Group Market News >. Symbol LSE:AVCT. 424 followers. Avacta sees substantial progress Friday, January 20, 2017 - 07:40 Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its Affimer technology in key applications, shareholders at the annual general meeting today will be told. Avacta Analytical, a leading provider of analytical services and technologies, has unveiled the Optim® 2 micro­volume protein analysis and characterisation instrument. VCTs Venture Capital Trust current launches, offers, prospectuses, applications, and reviews. Avacta & Oncosec to Collaborate on Innovative Gene Delivery Avacta Group plc and OncoSec Medical Incorporated recently announced they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse. Biotherapeutics and reagents developer Avacta Group said it had formed a co-development partnership with Bach BioSciences, a Get the latest up-to-the minute news on Avacta from ADVFNAvacta Group plc is a biotechnology company. ORD 10P quote : historical data and live quotes, charts, news, analyses, trading signals, calendar, informations and community tools UK protein scaffold specialist Avacta expects to seal its first licensing deal in 2017 due to its order book for Affimer projects swelling 70% YOY. , following its acquisition by Avacta Group Plc. Register now to create your own custom streaming stock watchlist. Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik 24 Jul 2018 Avacta Group PLC (LON:AVCT) - It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, 12:10, lantanatony: Yes The race is on, but are Avacta at the Races?! This information is provided by RNS, the news service of the London Stock Exchange. In order to exploit the rapidly growing interest in Avacta’s Avacta Group (GM) stock quote and AVCTF charts. Avacta to present pre-clinical development data at Lisbon conference Monday, November 12, 2018 - 13:43 Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. Home News Avacta Animal Health are now on Facebook! Avacta Animal Health are now on Facebook! 22nd July 2015 464 0 0. Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “The US is a very important and large market for us and in order to exploit the scale of the opportunity in North America effectively, we have decided to establish a presence on both the east and west coasts. 0 million (before expenses) by way of a placing of up to 1,760,000,000 new Ordinary Shares with both new and existing institutional Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, announces today that it has raised, subject to certain conditions, up to £22. The Wetherby-based firm is to start human trials in Avacta Group Plc (LON:AVCT) Share Price and News. It offers allergy, canine lymphona, and acute phase protein testing services and immunoassay kits. 8m from Avacta Animal Health. 18/09/2018 · Avacta Group Plc (LON:AVCT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. The last earnings update was 50 days ago. To exploit the rapidly growing interest in Avacta’s Avacta Animal Health. +44 (0)1223 75 Avacta News Feed. The developer of Affimer biotherapeutics and research reagents said operating losses rose to £3. FTSE index is seen opening 7 points lower on Wednesday, according to financial bookmakers. FTSE index is seen opening 7 points lower on Wednesday, according to financial bookmakers. Avacta Group, the Wetherby life sciences business developing Affimer biotherapeutics and reagents, has forged a licensing deal with New England Biolabs. avacta. Avacta Group, a UK-based healthcare technology and consumables business, has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space. Reuters provides trusted Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies Avacta Group's half year revenues increased 20% to £1. Avacta Group PLC (LON:AVCT) Share Price and News. Notes to Editors. Avacta Group, a spinout developing antibody alternatives, has secured £22m ($34. Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Avacta's revenues for the year to the end of July were on target at £2. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life …The interactive charting tool provides extensive upper and lower indicators, news and fundamental overlays, and comparison features. The following slide deck was published by Avacta Group Plc in conjunction with this event. The share data supplied on this page is provided by AJ Bell Media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock screeners and investor research tools. Each new subscriber gets a 10% discount and you get a free month off your bill every time. Life sciences firm Avacta Group has secured a new commercial license with a US specialist in the discovery and production of enzymes for molecular biology applications. Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in Avacta opens Wetherby lab Life sciences group Avacta has opened two new facilities in Wetherby and Cambridge. Basran would on Wednesday present recent data from pre-clinical development of the company's lead therapeutic programme, at the Protein EngineeringWe have a whole range of free CPD, blogs and other resources available for all veterinary professionals to make use of and share with their clients. It operates through the Life Sciences and Animal Health segments. ® is a registered trade mark. Avacta Group PLC is a United Kingdom based company, which caters to the healthcare sector. About us. Avacta Group plc is pleased to announce that the principal patent protecting the Affimer technology has been accepted for grant in the People’s Republic of China. 16 April 2018. Avacta Group plc (AIM: AVCT), the developer of Affimer ® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at BioTrinity Avacta stock quote and AVCT charts. 0m and pre-tax losses of £3. Avacta Analytical provides services and innovative instrumentation to the biopharmaceutical market. Christopher has 2 jobs listed on their profile. 9m from £2. Stock analysis for Avacta Group PLC (AVCT:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 5% by 2023 with ACUMEN PHARMACEUTICALS, ALSERES PHARMACEUTICALS, APOSENSE, AVACTA LIFE SCIENCES LIMITED, BANYAN Avacta Group plc is a leading, UK based healthcare equipment and instrumentation business, providing innovative technologies and services to the life sciences . The Leeds University spinout is commercialising affirmers, engineered proteins that mimic antibodies. Avacta is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Avacta Group plc's (formerly Readybuy plc) principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology is an engineered alternative to antibodies. (Sharecast News) - Avacta Group agreed a commercial Latest share prices for Avacta (AVCT) including charting, last trade, news, history and share dealing online, buy and sell Avacta shares. The company offers products which include optim and sensipod. UK news, historical stock charts, analyst ratings, financials, and today’s Avacta Group PLC stock price. Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the Shares Avacta's principal focus is on its proprietary Affimer ® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Avacta sees substantial progress Friday, January 20, 2017 - 07:40 Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its Affimer technology in key applications, shareholders at the annual general meeting today will be told. When there is no news about a firm the share price tends to decay anyway. Avacta stock quote and AVCT charts. , following its acquisition by Avacta Group Plc. Avacta Group plc is a biotechnology company. 7m small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases. The listed group reported revenues of £2. See the complete profile on LinkedIn and discover Christopher’s connections and jobs at similar companies. Affimer molecules have been developed for applications in diagnostics, drug / biomarker discovery, biotech research and development and therapeutics. com) Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. He was most recently chief executive of Immunocore, helping it to raise more than Biotechnology business Avacta Group, which has sites in Wetherby and Cambridge, has hailed the "significant operational progress" made during its latest financial year. Conversely YORKTEST Veterinary Services has announced a change of name to Avacta Animal Health Ltd. No news or research item is a personal recommendation to deal. AVACTA News, RNS and announcements including takeover bids, directors dealings, trading updates and annual and interim results statements23/11/2018 · Avacta forms collaboration pact with Tufts University in Boston. co. 31/07/2018. UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. 78 million, with losses through the year dipping from £7. High quality, robust, specific, with a rapid custom service and consistent batch reproducibility. Avacta Group plc has been awarded a grant to work with the Mary Lyon Centre at MRC Harwell to develop novel Affimer reagents which could help reduce the use of animals in life sciences research. At the time of the publication of the company’s half yearly report, the total order intake for custom Affirmers stands at £250k. Free real-time prices, trades, and chat. ©2015 Avacta Life Sciences Limited. Avacta Group, the developer of Affimer biotherapeutics and reagents is pleased to announce it has established a commercial team of three people in the US including the appointment of Dr Matthew Vincent as VP Therapeutics Business Development. : Get the latest Avacta Group stock price and detailed information including news, historical charts and realtime prices. Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research. Including historical share prices, analysis, earnings, cash flow and market valuation for Avacta Group PLC Avacta Life Sciences, a global provider of high quality reagents for life sciences, has launched a groundbreaking new website for its Affimer® technology. L). This is a About Avacta Group plc (www. 9 October 2014 | By kdm communications. Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. Stock analysis for Avacta Group PLC (AVCT:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile. However, the trade-off is …Avacta Group plc is a biotechnology company. 02/10/2018 Avacta is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress in San Diego on the 12 October 2018. This page features the latest news about the Avacta Group share. The move has seen the firm’s R&D costs jump to £3. The allergy testing and customer support that is synonymous with YORKTEST Veterinary Services will now appear under the brand name of SENSITEST ® - the complete allergy service. Dr. UK Stocks-Factors to watch on Oct 4 By Reuters - Oct 04, 2017 Oct 4 (Reuters) - Britain's FTSE 100 . 0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. I've held Avacta quite a few years and most of that time the company share price has been moribund. View the latest Avacta (AVCT) share price and news, including recent trades, historical charts, broker views and our views. Dive deeper with interactive charts and top stories of Avacta Group PLC. Avacta Animal Health is delighted to be exhibiting at this year’s London Vet Show (LVS), held at Olympia, London, from the 20th to the 21st of November. News. Avacta Group: Fundamentals Avacta Group: Recent Company News 10/10/2018 - 07:00, Avacta agrees Affimer reagent licensing deal, RNS. Therapies, Acute Phase Protein tests and Cyno-DIAL and Feli-DIAL tests are excluded from the offer. And this is a regular happenstance with Avacta. Avacta Group plc, the developer of Affimer biotherapeutics and research reagents, has announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in novel CAR-T cell-based immunotherapy. Avacta Group Plc is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. Losses from. Avacta is pleased to announce that it has agreed a commercial license with New England Biolabs, a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using Affimer technology. Forster served as Immunocore CEO until Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat. Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Sign in to uncover the email addresses for free. Avacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. com) Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Avacta Group plc, the developer of Affimer biotherapeutics and research reagents, has announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. – UK, Leeds – Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, is pleased to announce that it has appointed Dr Mike Owen to the Board as a non-executive director with immediate effect. Avacta Group PLC : Avacta’s CTO to Present at Major US ConferenceSource: Investigate Mining RSSPublished on 2018-10-11 View the latest share price for Avacta Group PLC [AVCT] and read the latest investors news and analysis from MoneyWeek. Affimer ® is a registered trade mark. S. Dr Trevor Nichols, who has acted as chairman of the Board since January 2014, will remain on the Board as a non-executive director. 75P from 1. avacta newsAvacta is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics Cambridge site. The core scaffold has two loops of nine amino acids. Avacta Group – a UK-based healthcare technology and consumables business – has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space. Dow Jones received a payment from EQS/DGAP to publish this press release. Avacta Group PLC. High quality, robust, with a 7 Avacta Group Plc (LON:AVCT) Share Price and News. Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in View the latest AVCT stock price with Barron's. . AVACTA GRP. UK Stocks-Factors to watch on Oct 4 By Reuters - Oct 04, 2017 Oct 4 (Reuters) - Britain's FTSE 100 . The latest Tweets from Avacta (@Affimers). Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Shares provides unbiased commentary, ideas, views and news on stocks, funds, pensions and savings. The licence deal followed a proof of concept study. However, the trade-off is …The interactive charting tool provides extensive upper and lower indicators, news and fundamental overlays, and comparison features. 7m and the group says trading is in line with management's expectations. uk/news/avacta-in-talks-with-pharmaDrug developer Avacta, which is working on cures for lung, breast and bowel cancer, said it is in discussions with a number of big pharmaceutical firms which could transform the group's fortunes. Avacta Animal Health invites members of the veterinary profession to join its free webinar hosted by CPD solutions on Canine Lymphoma, Current Perspectives on Diagnosis, Treatment and Monitoring on the 24 th April, when leading veterinarian Arno Roos will present the latest thinking on the diagnosis Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Read the news as it happens! Currently under development by Avacta Life Sciences, Affimer is an engineered protein scaffold derived from stefin A, a human protease inhibitor. com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings. com. Avacta Group plc's (formerly Readybuy plc) principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. , including the appointment of Dr. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. At Avacta Life Sciences, our mission is to create a high quality, powerful set of tools to help Life Scientists accelerate the understanding of biology and disease and to help them apply these advances to diagnosis and treatment. Losses from Avacta Group PLC Stock - AVCT. However, the Avacta appoints Eliot Forster as its new chairman. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, has signed a commercial license with New England Biolabs, a global leader in the discovery of enzymes. Matthew Vincent as Vice President Business Development focused on the North American market. engages in the provision veterinary laboratory services. Avacta Group PLC said on Thursday it has made strong technical and commercial progress, with revenue and loss for the six months ending January Subscribe now to see this Premium News article This page features the latest news about the Avacta Group stock. Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, has signed a commercial license with New England Biolabs, a global leader in the discovery of enzymes. Basran would on Wednesday present recent data from pre-clinical development of the company's lead therapeutic programme, at the Protein EngineeringAbout Avacta Group plc (www. Avacta has developed Affimer technology - a revolutionary new engineered affinity protein that is an alternative to antibodies. For the year ending 31 Regional business news for Yorkshire This page features the latest news about the Avacta Group share. 5m from Avacta Life Sciences and £0. The group has three divisions. Avacta Group plc (OTC:AVCTF) and OncoSec Medical Incorporated (NASDAQ: ONCS), are pleased to announce they have entered into a research collaboration to combine Avacta's Affimer protein platform Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, has signed a commercial license with New England Biolabs, a global leader in the discovery of enzymes. This page features the latest news about the Avacta Group stock. Basran would on Wednesday present recent data from pre-clinical development of the company's lead therapeutic programme, at the Protein EngineeringHardman & Co call the lithium market: is a change in trend happening? 23 rd November 2018. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. Reuters provides trusted Avacta Group plc (AIM: AVCT), the developer of Affimer ® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at BioTrinity Avacta Life Sciences, a global provider of high quality reagents for life sciences, has launched a groundbreaking new website for its Affimer® technology. The move, which follows the recent acquisition of affinity reagents specialist Aptuscan, brings together the entire Avacta Group on the same site. Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. As well as high throughput, a big advantage of the Optim 1000 is the small sample volume required – down to 9 µl – which is perfect for us. avacta. com/topics/avacta24/10/2018 · About Evolution We are a leading provider of bespoke professional Executive Search services, specialising in sourcing elite candidates for the biotechnology, biopharmaceutical, Life Sciences & related industries. Avacta Life Sciences' (ALS) deal with Moderna Therapeutics to develop a range of Affimer-based biotherapeutic candidates is transformational, not only providing an opportunity to increase the value of Affimers as any clinical products progress, but also balancing the company's risk profile and reducing the reliance on Affimers as reagents. Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. Avacta Group said it had appointed Eliot Forster as its new chairman, replacing Trevor Nichols, who would remain as a non-executive director. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and gen eral research and development. Avacta's principal focus is on its proprietary Affimer® platform, a novel engineered alternative to Cambridge site. York biotechnology business Avacta has formed a partnership with Pall Life Sciences. Avacta news and AVCT price. 0 million (before expenses) by way of a placing of up to 1,760,000,000 new Ordinary Shares with both new and existing institutional The collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry Generation of a new class of highly targeted bio-therapeutics as a potentially superior alternative to antibody drug conjugates (ADCs), a market estimated to be w Avacta Group posted a slightly wider full-year loss on Wednesday even as it highlighted progress both with its in-house programmes and third parties. Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat. Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in Has Avacta Group been receiving favorable news coverage? News headlines about AVCT stock have trended negative this week, according to InfoTrie. The latest Tweets from Avacta (@Affimers). Avacta Group Plc engages in the provision of proprietary solutions to the healthcare sector. Updated key statistics for Avacta Group PLC - including rtq margins, P/E ratio, valuation, profitability, company description, and other stock analysis data. Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialize a product using the Affimer technology for use in both life science research and diagnostics Avacta Life Sciences, Wetherby. The listed group reported revenues of £2. Latest stock price today and the US's most active stock market forums. Avacta Group PLC (LON:AVCT) Share Price and News. Avacta has developed Affimer technology, an engineered alternative to antibodies. L), an AIM listed company which provides novel detection and analysis technology for the pharmaceutical, defence/ security and clinical diagnostics markets, announces that it has appointed Daniel Stewart & Company plc as the Company's Nominated Adviser and Joint Broker with immediate effect. Avacta Group - Recent News & Activity | Crunchbase Avacta's principal focus is on its proprietary Affimer ® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics A team of researchers from the University of Leicester has helped Avacta Animal Health Ltd to develop a new user-friendly electronic system for diagnosing lymphoma in dogs in the early stages, and View the latest AVCT stock quote and chart on MSN Money. You can Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Affimers - an engineered alternative to antibodies – can be used in scientific research, diagnostics and in the development of therapeutics. After initial discussions with Avacta, we sent some samples for analysis and were impressed by the Company’s approach and responsiveness. Avacta 'delighted' at license agreement with longtime collaborator 10 October 2018 16:33 (Sharecast News) - Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise Avacta Group plc is a biotechnology company. 74m in 2017. yahoo. 8m were up from £2. Avacta is a pre-clinical stage biotechnology company developing biotherapeutics based on its proprietary Affimer protein technology that benefits from near-term revenues from research and diagnostic reagents. Invest with The Share Centre Avacta Group has agreed a co-development partnership with Bach BioSciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston. Home General News Avacta also made progress in the export market as Avacta Health’s canine lymphoma blood test (‘cLBT’) is now available for purchase in the US. Free registration. Contact and general information about the website avacta. Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Meanwhile biotech firm Avacta was able to raise £11. com). Avacta's principal focus is on its proprietary Affimer ® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Paul Mylchreest, Mining Analyst at Hardman and Co updates the market on the fundamentals driving Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in diagnostics, therapeutics and research. The AIM-listed group acquired the intellectual property for Affimer technology from Leeds University in 2012 and began commercialization in 2014. Vincent is a senior executive with over 25 years’ experience in multiple areas of biotechnology and life science. The data, expected in the next month or so, will keep the biotech firm on track to take the first Affimer candidate into phase 1 studies, targeted for 2019The interactive charting tool provides extensive upper and lower indicators, news and fundamental overlays, and comparison features. Based on a small protein, Affimer technology Avacta Licenses Affimer Tech to New England BiolabsSource: Genomeweb Molecular DiagnosticsPublished on 2018-10-11 Avacta (AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Compare across sectors, industries & regions. Avacta operates through three divisions: Avacta Analytical – High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development. Paul Mylchreest, Mining Analyst at Hardman and Co updates the market on the fundamentals driving Avacta Group plc is a biotechnology company. Avacta stock quote and AVCT charts. Profile page - Avacta Group PLC Share Price and News. Avacta Group Plc (), a UK£27. Avacta Group Plc (LON:AVCT) said its lead PD-L1 programme was on track to deliver key pre-clinical milestones this year. Latest Breaking news and Headlines on AVACTA GROUP PLC ORD NEW (AVCTF) stock from Seeking Alpha. This compact and robust system combines the powerful protein characterisation capabilities of the original Optim 1000 instrument Looking for news, check out the new FREE CenterWatch Weekly! The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Avacta Group Plc (LON:AVCT) has signed a licensing deal with New England Biolabs (NEB), an enzyme discovery and production company, to commercialise its Affimer technology for use in life science Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, announces today that it has raised, subject to certain conditions, up to £22. Avacta said Pall will use the18/09/2018 · Avacta Group Plc (LON:AVCT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. Eliot brings over 25 years of experience in the pharmaceutical and biotechnology Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes news Software updates simplify protein analysis for Avacta’s Optim® instruments Browse News by Company ACD Bio Agilent Technologies Bayer Bio-Rad bluebird bio Boehringer Ingelheim Celgene GE Healthcare Genentech GSK Illumina Johnson & Johnson Juno Therapeutics KITE Pharma Lonza Merck MilliporeSigma Novartis Pfizer Roche Sanofi Sartorius Stedim Sigma-Aldrich Singulex Thermo Fisher Scientific Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce the appointment of Philippe Cotrel as Chief Commercial Officer of Avacta, with immediate effect. Avacta Group Plc (LON:AVCT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. Matthew Vincent as Vice President Therapeutics Business Development. Stride Gaming, owner of Kitty Bingo and host of similar websites, saw shares fall 32 per cent this week. Hardman & Co Research Hardman & Co Research: Avacta (AVCT): Gearing up the management team 26-Jun-2018 / 13:30 Avacta is listed on the London Stock Exchange with ticker code AVCT, and is part of the Pharmaceuticals & Biotechnology sector. Avacta Animal Health Ltd. Change the date range and chart type, and compare AVACTA GROUP PLC ORD 10P against other companies. However, the trade-off is AVCTRead More LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to progress Affimer. About Avacta Group plc (www. 8 million grant by the Medical Research Council to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate Avacta Group Plc (LON:AVCT) have seen their losses for the second half widen with a 31% increase in research and development. Jul 24, 2018 Avacta Group PLC (LON:AVCT) - It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, 12:10, lantanatony: Yes The race is on, but are Avacta at the Races?! This information is provided by RNS, the news service of the London Stock Exchange. The new locations almost double the firm’s overall footprint, which increases from 9,500 to 18,500 sq ft, including new state-of-the-art laboratory facilities. 7m and the group says trading is in line with management's expectations. AVACTA News, RNS and announcements including takeover bids, directors dealings, trading updates and annual and interim results statementsAvacta Group earned a news sentiment score of -1. It develops medical diagnostic products such as reagents and arrays which are helpful in drug discovery. Avacta Group plc is a biotechnology company. Avacta's principal focus is on its proprietary Affimer® platform, a novel engineered alternative to Real-time share price updates and latest news for Avacta Group (LSE:AVCT). Sector insights The latest news, investment ideas and research insights from different sectors across the globe. Avacta Group, the developer of Affimer biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy has successfully completed a proof-of-concept study with encouraging data, showing sustained production of Affimer molecules by the muscle tissue of mice Avacta Group plc, the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta’s Affimer technology. The allergy testing and customer support that is synonymous with YORKTEST Veterinary Services will now appear under the brand name of SENSITEST ® - the complete allergy service. 7m gross proceeds through a placing of new Avacta stock quote and AVCT charts. Get a £25 credit by sharing with your friends and colleagues via the share buttons below. Avacta’s policies section includes the handbook and other useful documentation, while the operations area includes details of proper emergency and contingency procedures Drug developer Avacta, which is working on cures for lung, breast and bowel cancer, said it has made significant progress over the past year. Affimers represent a radical alternative to the established antibody technology, which In the meantime, Avacta continues to develop Affimers that bind to targets as diverse as the Zika virus, PD-L1 commonly targeted in cancer immunotherapy, and somewhat bizarrely, the explosive TNT. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Avacta Group plc (www. Highly experienced pharma/biotech professional to lead Avacta's Board Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce the appointment Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), discusses with Proactive Investors a licensing deal they've signed with New England Biolabs (NEB), an enzyme discovery and Avacta Group News: This is the News-site for the company Avacta Group on Markets Insider Biotechnology business Avacta Group, which has sites in Wetherby and Cambridge, has appointed a new chairman. Avacta Life Sciences was established in 2012 (as part of the Avacta Group) to develop and commercialise its Affimer technology. Avacta Group News Avacta to present pre-clinical development data at Lisbon conference Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week. Losses fromThe collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry Generation of a new class of highly targeted bio-therapeutics as a potentially superior alternative to antibody drug conjugates (ADCs), a market estimated to be w Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Avacta Group plc the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for Avacta Group Plc (LON:AVCT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. Shares in life sciences group Avacta (LSE: AVCT) have jumped by as much as a quarter today after the company announced that it had entered into a collaboration, licensing and option agreement with Avacta Group plc is a biotechnology company. 02/10/2018 Avacta is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics Avacta News Feed. - View more Trades, Directors' Deals, and Broker Ratings. View the latest share price for Avacta Group PLC [AVCT] and read the latest investors news and analysis from MoneyWeek. The goal of the co-operation is to assess the suitability of developing gene therapies that use FIT Biotech’s gtGTU platform and Avacta’s Affimer technology. Press Releases. 225 likes · 1 was here. 39 million. 76m for the year ending 31 July 2018, up slightly from £2. Avacta Group plc ("Avacta" or "the Company") Change of Adviser Avacta Group plc (Stock Code: AVCT. Great investment tools with live data. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share priceDrug developer Avacta, which is working on cures for lung, breast and bowel cancer, has signed a commercial license with New England Biolabs, a global leader in the discovery of enzymes. A look at the shareholders of Avacta Group Plc (LON:AVCT) can tell us which group is most powerful. this is very good news for the company given NEB represents a third party endorsement from a highly prestigious partner for Avacta’s Affimer technology platform. Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. avacta news Nov 1 (Reuters) - Avacta Group PLC: * Panmure Gordon starts Avacta Group Plc with buy For a summary of rating actions and price targe LONDON, Feb 23 (Reuters) - Avacta Group PLC: * Signs a sales About Avacta Group plc (www. Allergens enter the body and cause the immune system to overreact and produce antibodies, which manifests as an allergic response. The Wetherby-based firm Cambridge life science business Avacta Group, quoted in the UK on AIM, has set up a potentially lucrative royalty stream through a licensing deal with New England Biolabs® (NEB) in Massachusetts. View Christopher Gray’s profile on LinkedIn, the world's largest professional community. Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy has successfully completed a proof-of-concept study with very encouraging data, showing sustained production of Affimer molecules by the muscle tissue of mice. Paul Mylchreest, Mining Analyst at Hardman and Co updates the market on the fundamentals driving The share data supplied on this page is provided by AJ Bell Media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock screeners and investor research tools. Corporate Team advises Avacta Group plc on proposed placing Print news article. By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest. See who you know at Avacta, leverage your professional network, and get hired. Our focus is to equip customers with a broad range of capabilities, enabling them to develop their therapeutics quicker, cheaper and better. However, the trade-off is …Avacta Life Sciences, a global provider of high quality reagents for life sciences, has launched a groundbreaking new website for its Affimer® technology. 89 million to £10. 6 million. The maximum number of items an individual practice can earn is 5, which would equate to 25 tests. Avacta Group plc ("Avacta", the "Company" or the "Group") Interim Results for the Period Ended 31 January 2018 Avacta Group plc (AIM: AVCT), the developer of Affimer ® biotherapeutics and research reagents, announces its unaudited interim results for the period ended 31 January 2018. The company was founded in 1999 and is headquartered in Wetherby, the United Kingdom. Join LinkedIn today for free. 8m grant by the Medical Research Council. com/news/avacta-group-plc-lon-avct-10003727618/09/2018 · Avacta Group Plc (LON:AVCT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. CAR-T cell therapy is a major new About us. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer Avacta Group plc, the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that a collaborative development programme with Leeds University has been awarded a £3. The reagents developer said Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. 7 on InfoTrie's scale. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. SC037861. Cambridge Life Science company Avacta Group plc says it is on the cusp of securing a number of licensing deals on the back of escalating partnerships with global players. Read all the latest Avacta Group plc (AVCT) Ordinary Shares 10p share news, regulatory announcements and tips. - News - PharmaTimesBiotherapeutics and reagents developer Avacta Group plc has established a commercial team in the United States of America, including the appointment of Dr Matthew Vincent as Vice President, Therapeutics Business Development based in Boston. Avacta Group plc, the developer of Affimer biotherapeutics and reagents, appointed Dr Eliot Forster as Non-Executive Chairman to the Board with immediate effect. - Gain access to LIVE real-time Regulatory News (RNS). About Avacta Analytical Headquartered in Wetherby, UK, with a network of distributors, partners and applications laboratories in all the major continents of the world, Avacta Analytical provides innovative instrumentation to the biopharmaceutical market. Avacta Group plc, the science-led healthcare supplier, has announce that a collaborative programme with Leeds University has been awarded a £3. The share data supplied on this page is provided by AJ Bell Media and incorporates share prices, market news, indices, charts, fundamentals, heatmaps, stock screeners and investor research tools. Avacta Group plc is dedicated to providing Life Scientists with high quality, powerful, unique tools to enable them to work faster and smarter in accelerating our understanding of biology and disease, and to help them apply these advances to diagnosis and treatment of humans and animals. Avacta Group, the developer of Affimer ® biotherapeutics and reagents, and OncoSec Medical, a company developing intratumoral cancer immunotherapies, have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse ®. FREE Member Services - Setup a personalised Watchlist and Virtual Portfolio. Follow News can include everything from the results of departmental audits to charity events and regular club activities. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. Biotechnology business Avacta Group has appointed Philippe Cotrel as chief commercial officer. Avacta Group is a biotech business whose shares are trading at just over 1p each. This is a Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. This expansion is a strong signal of our confidence in the Avacta's principal focus is on its proprietary Affimer ® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. Avacta develops detection and analysis technology aimed primarily at the pharmaceutical and healthcare markets and has lately entered the field of clinical diagnostics. yorkshirepost